secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOXYTRAN, INC (BIXT)
CIK:        0001445815
Form:       8-K
Filed at:   2022-01-14T23:59:59+00:00
Accession:  0001539497-22-000063
Event type: debt
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioxytran issues $1.467M in 1-year 6% convertible notes at $0.25; also releases corporate presentation
--------------------------------------------------------------------------------

- Entered 34 Note Purchase Agreements for $1,467,000 principal in convertible notes due Jan 10, 2023; 6% interest, conversion at $0.25/share.
- Net cash reduced by $86,040; aggregate discount of $128,290 includes 264,060 five-year warrants at $0.25 issued to placement agent WallachBeth Capital.
- Board approved the agreements on Jan 10, 2022; notes issued same day.
- Filed corporate presentation (Exhibit 99.1) on Jan 12, 2022 outlining pharmaceutical development status (no specific content provided).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1445815/000153949722000063/0001539497-22-000063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1445815/000153949722000063/n2583_x16-8k.htm
  HTML page:      https://secwatch.observer/filing/0001539497-22-000063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer